AstraZeneca PLC
corporate_fare Company Profile
AstraZeneca PLC (NYSE:AZN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 53 items for AZN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-21, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 18 rated 8 or above. Recent SEC coverage for AZN spans 6-K.
Recent high-impact activity:
- EU Regulators Back AstraZeneca's Klygefa for Myasthenia Gravis
- Enhertu Gets EU CHMP Backing for Early Breast Cancer — 53% Recurrence Risk Cut
- AstraZeneca CEO Pascal Soriot Buys £7.3M of Company Stock
- AstraZeneca's Etcamah Misses Primary Endpoint in SERENA-4 Phase III Trial
- Imfinzi + Imdelltra Hits OS Endpoint in Phase III ES-SCLC Trial
Financial Snapshot
Insider Transactions
AZN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.